Last reviewed · How we verify

Total Glucosides Paeony Capsules

Sun Yat-sen University · FDA-approved active Small molecule

Total Glucosides of Paeony (TGP) modulates immune function and reduces inflammatory responses through multiple pathways including T cell regulation and cytokine suppression.

Total Glucosides of Paeony (TGP) modulates immune function and reduces inflammatory responses through multiple pathways including T cell regulation and cytokine suppression. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Other autoimmune and inflammatory disorders.

At a glance

Generic nameTotal Glucosides Paeony Capsules
SponsorSun Yat-sen University
Drug classHerbal extract immunomodulator
ModalitySmall molecule
Therapeutic areaImmunology / Rheumatology
PhaseFDA-approved

Mechanism of action

TGP is a standardized extract from Paeonia lactiflora that acts as an immunomodulator, primarily by promoting regulatory T cell differentiation and suppressing pro-inflammatory cytokine production. It has been shown to inhibit Th1/Th17 cell differentiation while enhancing Treg cell development, making it useful in autoimmune and inflammatory conditions. The mechanism involves modulation of NF-κB signaling and other intracellular pathways involved in immune activation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: